Core Insights - The Ademi Firm is investigating Repare for potential breaches of fiduciary duty related to its transaction with XenoTherapeutics [1][3] - Repare shareholders are set to receive approximately $1.82 per share in cash at closing, along with a non-transferable contingent value right (CVR) per share [2] - The CVRs will entitle shareholders to a percentage of future proceeds from partnerships with Bristol-Myers Squibb, Debiopharm, and DCx Biotherapeutics, with percentages ranging from 90% to 75% over a 10-year period [2] Transaction Details - The final cash payment to Repare shareholders will depend on the company's cash balance at closing after deducting transaction costs and liabilities [2] - The transaction agreement includes provisions that limit competing offers for Repare, imposing penalties for accepting alternative bids [3] Investigation Focus - The investigation by the Ademi Firm centers on whether the Repare board of directors is adequately fulfilling their fiduciary duties to all shareholders amid the transaction [3]